Liquidia Corp — Investor Relations & Filings

Liquidia Corp is a biopharmaceutical company dedicated to the development and commercialization of therapies for rare cardiopulmonary diseases. The company focuses on addressing unmet needs in conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). A core component of its strategy is the proprietary PRINT® technology, a particle engineering platform used to create precisely uniform drug particles. This technology is designed to enhance the efficacy, tolerability, and convenience of medicines, particularly through innovative delivery methods like inhaled therapies. Liquidia's pipeline is focused on advancing treatments to improve outcomes for patients with these serious diseases.